


CLAIMS

1. Peptide analogs of nociceptin having general formula (I) :



(I)

wherein

Ψ represents the bond between the first two aminoacidic residues and is selected from CO-NH and CH₂-NH; **Xaa**⁴ is selected from pXPhe where “X” represents H, Cl, Br, I, F, NO₂, CN and “p” indicates the para- position of the phenyl ring of Phe, Tic, Phg, Atc, Aic, which represent tetrahydroisochinolin-3-carboxylic acid, phenylglycin, aminotetralincarboxylic acid, aminoindancarboxylic acid, respectively; **Xbb**¹⁴ is selected from Trp, Arg, Lys, Leu, Orn, homoArg, diaminobutyric acid, diaminopropionic acid; **Xcc**¹⁵ is selected from Phe, Arg, Lys, Ala, Orn or Trp; **R** represents a terminal amide group (-NH₂) or a terminal carboxy group (-OH); wherein the aminoacidic residues or derivatives thereof can be in D or L configuration; and pharmaceutically acceptable salts thereof.

2. Peptide according to Claim 1, wherein Ψ is CO-NH or CH₂-NH; **Xaa**⁴ is Phe, pClPhe, pBrPhe, pIPhe, PNO₂Phe or pCNPhe; **Xbb**¹⁴ is Arg, Lys, Leu, Orn; **Xcc**¹⁵ is Arg, -Lys, Ala, Orn or Trp, **R** is -NH₂ or -OH.

3. Peptide according to Claim 2, wherein Ψ is CO-NH or CH₂-NH; **Xaa**⁴ is L-pFPhe or L-PNO₂Phe; **Xbb**¹⁴ is L-Arg, L-Lys, or L-Leu; **Xcc**¹⁵ is L-Arg, L-Lys or L-Ala; **R** is -NH₂.

4. Peptide according to Claim 3, selected from the group consisting of:

Ψ is CO-NH; **Xaa**⁴ is Phe(pF); **Xbb**¹⁴ is Arg; **Xcc**¹⁵ is Lys; **R** is NH₂

Ψ is CH₂-NH; **Xaa**⁴ is Phe(pF); **Xbb**¹⁴ is Arg; **Xcc**¹⁵ is Lys; **R** is NH₂

Ψ is CO-NH; **Xaa**⁴ is Phe(pF); **Xbb**¹⁴ is Arg; **Xcc**¹⁵ is Lys; **R** is OH

- V. Ψ is $\text{CH}_2\text{-NH}$; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Lys; R is OH
- VI. Ψ is CO-NH ; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Arg; R is NH_2
- VII. Ψ is $\text{CH}_2\text{-NH}$; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Arg; R is NH_2
- Ψ is CO-NH ; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Arg; R is OH
- Ψ is $\text{CH}_2\text{-NH}$; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Arg; R is OH
- Ψ is CO-NH ; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is D-Lys; R is NH_2
- Ψ is $\text{CH}_2\text{-NH}$; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is D-Lys; R is NH_2
- Ψ is CO-NH ; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is D-Lys; R is OH
- Ψ is $\text{CH}_2\text{-NH}$; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is D-Lys; R is OH
- Ψ is CO-NH ; Xaa^4 is Phe(pF); Xbb^{14} is D-Arg; Xcc^{15} is Lys; R is NH_2
- Ψ is $\text{CH}_2\text{-NH}$; Xaa^4 is Phe(pF); Xbb^{14} is D-Arg; Xcc^{15} is Lys; R is NH_2
- Ψ is CO-NH ; Xaa^4 is Phe(pF); Xbb^{14} is D-Arg; Xcc^{15} is Lys; R is OH
- Ψ is $\text{CH}_2\text{-NH}$; Xaa^4 is Phe(pF); Xbb^{14} is D-Arg; Xcc^{15} is Lys; R is OH
- Ψ is CO-NH ; Xaa^4 is Phe(pF); Xbb^{14} is D-Arg; Xcc^{15} is D-Lys; R is NH_2
- Ψ is $\text{CH}_2\text{-NH}$; Xaa^4 is Phe(pF); Xbb^{14} is D-Arg; Xcc^{15} is D-Lys; R is NH_2
- Ψ is CO-NH ; Xaa^4 is Phe(pF); Xbb^{14} is D-Arg; Xcc^{15} is D-Lys; R is OH
- VIII. Ψ is $\text{CH}_2\text{-NH}$; Xaa^4 is Phe(pF); Xbb^{14} is D-Arg; Xcc^{15} is D-Lys; R is OH
- IX. Ψ is CO-NH ; Xaa^4 is D-Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Lys; R is NH_2
- X. Ψ is $\text{CH}_2\text{-NH}$; Xaa^4 is D-Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Lys; R is NH_2
- Ψ is CO-NH ; Xaa^4 is D-Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Lys; R is OH
- Ψ is $\text{CH}_2\text{-NH}$; Xaa^4 is D-Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Lys; R is OH
- Ψ is CO-NH ; Xaa^4 is Phe(pNO₂); Xbb^{14} is Arg; Xcc^{15} is Lys; R is NH_2
- Ψ is $\text{CH}_2\text{-NH}$; Xaa^4 is Phe(pNO₂); Xbb^{14} is Arg; Xcc^{15} is Lys; R is NH_2
- Ψ is CO-NH ; Xaa^4 is Phe(pNO₂); Xbb^{14} is Arg; Xcc^{15} is Lys; R is OH

Ψ is CH₂-NH; Xaa⁴ is Phe(pNO₂); Xbb¹⁴ is Arg; Xcc¹⁵ is Lys; R is OH
 Ψ is CO-NH; Xaa⁴ is Phe(pNO₂); Xbb¹⁴ is Arg; Xcc¹⁵ is Arg; R is NH₂
 Ψ is CH₂-NH; Xaa⁴ is Phe(pNO₂); Xbb¹⁴ is Arg; Xcc¹⁵ is Arg; R is NH₂
 XI. Ψ is CO-NH; Xaa⁴ is Phe(pNO₂); Xbb¹⁴ is Arg; Xcc¹⁵ is Arg; R is OH

Ψ is CH₂-NH; Xaa⁴ is Phe(pNO₂); Xbb¹⁴ is Arg; Xcc¹⁵ is Arg; R is OH
 Ψ is CO-NH; Xaa⁴ is Phe(pNO₂); Xbb¹⁴ is Arg; Xcc¹⁵ is D-Lys; R is NH₂
 Ψ is CH₂-NH; Xaa⁴ is Phe(pNO₂); Xbb¹⁴ is Arg; Xcc¹⁵ is D-Lys; R is NH₂
 Ψ is CO-NH; Xaa⁴ is Phe(pNO₂); Xbb¹⁴ is Arg; Xcc¹⁵ is D-Lys; R is OH
 Ψ is CH₂-NH; Xaa⁴ is Phe(pNO₂); Xbb¹⁴ is Arg; Xcc¹⁵ is D-Lys; R is OH
 Ψ is CO-NH; Xaa⁴ is Phe(pNO₂); Xbb¹⁴ is D-Arg; Xcc¹⁵ is Lys; R is NH₂
 Ψ is CH₂-NH; Xaa⁴ is Phe(pNO₂); Xbb¹⁴ is D-Arg; Xcc¹⁵ is Lys; R is NH₂
 Ψ is CO-NH; Xaa⁴ is Phe(pNO₂); Xbb¹⁴ is D-Arg; Xcc¹⁵ is Lys; R is OH
 Ψ is CH₂-NH; Xaa⁴ is Phe(pNO₂); Xbb¹⁴ is D-Arg; Xcc¹⁵ is Lys; R is OH
 Ψ is CO-NH; Xaa⁴ is Phe(pNO₂); Xbb¹⁴ is D-Arg; Xcc¹⁵ is D-Lys; R is NH₂
 Ψ is CH₂-NH; Xaa⁴ is Phe(pNO₂); Xbb¹⁴ is D-Arg; Xcc¹⁵ is D-Lys; R is NH₂
 Ψ is CO-NH; Xaa⁴ is Phe(pNO₂); Xbb¹⁴ is D-Arg; Xcc¹⁵ is D-Lys; R is OH
 Ψ is CH₂-NH; Xaa⁴ is Phe(pNO₂); Xbb¹⁴ is D-Arg; Xcc¹⁵ is D-Lys; R is OH
 Ψ is CO-NH; Xaa⁴ is D-Phe(pNO₂); Xbb¹⁴ is Arg; Xcc¹⁵ is Lys; R is NH₂
 Ψ is CH₂-NH; Xaa⁴ is D-Phe(pNO₂); Xbb¹⁴ is Arg; Xcc¹⁵ is Lys; R is NH₂
 XII. Ψ is CO-NH; Xaa⁴ is D-Phe(pNO₂); Xbb¹⁴ is Arg; Xcc¹⁵ is Lys; R is OH

Ψ is CH₂-NH; Xaa⁴ is D-Phe(pNO₂); Xbb¹⁴ is Arg; Xcc¹⁵ is Lys; R is OH

5. Peptide according to Claim 4, selected from the group consisting of:

a) H-Phe-Gly-Gly-(pF)Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Arg-Lys-Asn-Gln-NH₂

b) H-Phe- Ψ (CH₂NH)-Gly-Gly-(pF)Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Arg-Lys-Asn-Gln-NH₂

6. Pharmaceutical composition containing a peptide according to Claim 1, together with pharmaceutically acceptable excipients.
7. A method for treating disorders conditions or pathological states in which it is desirable to obtain the activation of the NOP receptors, said method comprising administering an effective amount of a peptide according to Claim 1 to a patient in need of such a treatment.
8. A method according to Claim 7, wherein said disorder condition or pathological state is selected from the group consisting of hypertension, tachycardia, water-retaining diseases, hyponatremia, heart failure, motility dysfunctions of the smooth muscle in the gastrointestinal, respiratory and genitourinary tracts, inflammatory states, peripheral and spinal analgesia, inhibition of cough.
9. A method according to Claim 7, wherein said disorder condition or pathological state is urinary incontinence due to neurogenic bladder and bladder hyperactivity.
10. A method according to Claim 7, wherein said disorder condition or pathological state is cough.
11. A method according to Claim 7, wherein said disorder condition or pathological state is gastrointestinal hypermotility.
12. A method according to Claim 7, wherein said disorder condition or pathological state is hyponatremia heart failure and hypertension.
13. A method according to Claim 7, wherein said disorder condition or pathological state is chronic pain.
14. A method according to Claim 7, wherein said patient is a mammalian.
15. A method according to Claim 7, wherein said patient is a human being.